ClinicalTrials.gg
RecruitingNCT04637711Updated Nov 20, 2020

Surgical Intervention for Refractory Granulomatous Lobular Mastitis

An interventional study of Focus clearing + whole breast exploration and washing + one-stage micro plastic surgery No Intervention: Extensive lesion excision in Refractory Granulomatous Lobular Mastitis, sponsored by Wuhan University. Recruiting at 1 site in China. Open to female participants aged 18 Years to 60 Years. Per ClinicalTrials.gov, last updated 2020-11-20.

Sponsored by Wuhan University · Not applicable, Interventional, and Treatment

From the registry’s dates

  • Primary completion was expected by Jun 2022, 4 years 4 months ago, but the record still lists the study as recruiting.
  • Started Nov 2020; still recruiting 6 years later.
Phase
Not applicable
Study type
Interventional
Enrollment
300
Allocation
Randomized
Ages
18 Years to 60 Years
Sex
Female
01

Study summary

Granulomatous lobular mastitis (GLM) belongs to a group of benign diseases, which is mainly treated with glucocorticoids and surgical treatment. Nowadays, in China, surgical treatment has gradually become the mainstream, but the timing and the extent of surgery are still controversial, and different literatures report that the recurrence rate after surgery is 20-50%. Empirical lesion resection is generally used. We believe that the main reason for the high recurrence rate is the incomplete removal of the breast lesions. Because GLM is often characterized with microabscesses formation, empirical resection is likely to have residual lesions that are not visible to the naked eye. In order to reduce the postoperative recurrence rate and protect the breast appearance as much as possible, we propose a surgical plan : granulomatous lobular mastitis "lesion removal + whole breast exploration and flushing + one-stage microplastic surgery". The purpose of this study was to compare this surgical scheme of granulomatous lobular mastitis with existing surgical schemes, and to compare the overall benefits of the two for patients with GLM. We aim to protect the breast appearance on the premise of low recurrence, improve the quality of life of GLM patients, and standardize GLM surgical schemes.

02

Conditions studied

  • Refractory Granulomatous Lobular Mastitis

Browse trials for

Keywords

  • granulomatous lobular mastitis ;refractory;surgery
03

In context

Mastitis

31 studies on the registry are indexed under Mastitis; 7 are open to participants now.

This study's planned enrollment of 300 is above the median of 114 across 16 interventional studies indexed under Mastitis.

Browse Mastitis studies →

Lead sponsor

Wuhan University is the lead sponsor of 46 studies on the registry; 14 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 60 Years
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients aged 18 years or older with granulomatous lobular mastitis
  • Patients without surgical treatment;
  • Extensive lesions involving two or more quadrants of the breast, or accompanied by abscess, sinus fistula formation, skin rupture and other complex lesions;
  • Patients volunteered to participate in the study after .

Exclusion criteria

Exclusion Criteria:

  • Patients were diagnosed with mastitis with other definite etiology confirmed by pathology
  • Patients who chose conservative treatment and did not receive surgical treatment
  • Combined with other basic diseases, unable to tolerate surgery
  • Patients in pregnancy.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
300 participants (estimated)

Study arms

  • Experimental
    Specific surgical Intervention

    Focus clearing + whole breast exploration and washing + one-stage micro plastic surgery

    Procedure: Focus clearing + whole breast exploration and washing + one-stage micro plastic surgery No Intervention: Extensive lesion excision

  • No intervention
    Extensive lesion excision

Interventions

  • ProcedureFocus clearing + whole breast exploration and washing + one-stage micro plastic surgery No Intervention: Extensive lesion excision

    Only visible lesions and necrotic tissues, such as abscess cavity, sinus tract and fistula, were removed intraoperatively, while normal glands and fat were retained. Preoperative ultrasound was used to locate the lesion area and then the surgical incision was designed. Intraoperative ultrasound examination of latent small lesions, resection of lesions visible under ultrasound, and then a full breast exploration, one finger page incision interval.Radially cut from the base to the subcutaneous, lesions were found and treated locally. After removal of lesion, fully using the syringe, in turn, use of 3% hydrogen peroxide solution, 1% eniodine, saline water is widely jet pulse washing, and around the lesions base. After rinsing, soak in 1% active iodine for 10min, then rinse with normal saline until the liquid is clear. Breast tumor Surgery (Oncoplastic Breast Surgery, OBS) core technology (volume replacement and volume replacement).

06

What researchers measure

Primary outcomes

  1. Recurrence rate

    Inflammatory changes, mass, abscess or fistula formation, nodular erythema of the upper and lower extremities and joint pain occurred in the ipilateral breast within one year after surgery was defined as recurrence.

    Time frame: Up to 2 years

Secondary outcomes

  1. Breast appearance and cosmetic effect score

    Refer to Harris standard to evaluate postoperative cosmetic effect. Specify the breast appearance and cosmetic effect rating table.

    Time frame: Up to 2 years

  2. Surgical incision healing time

    Surgical incision healing time was defined as the time from the first day after the operation to the healing time of the surgical incision. The wound surface was dry, there was no effusion, and no surgical incision complications occurred

    Time frame: Up to 2 months

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Nov 20, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04637711
Lead sponsor
Wuhan University
Responsible party
Gaosong Wu, Ph D, MD (Chair, Department of Thyroid and Breast Surgery, Zhongnan Hospital of Wuhan University, Wuhan University) — Principal investigator
First posted
Nov 20, 2020
Start date
Nov 1, 2020
Primary completion
Jun 30, 2022 (estimated)
Completion
Jun 30, 2027 (estimated)
Last update
Nov 20, 2020

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion